Biomarker for Patients With Fabry Disease (BioFabry) (NCT02778295) | Clinical Trial Compass
WithdrawnNot Applicable
Biomarker for Patients With Fabry Disease (BioFabry)
Stopped: Transition into BioMetabol
Germany, India, Sri Lanka0Started 2018-08-20
Plain-language summary
Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood
Who can participate
Age range2 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
INCLUSION CRITERIA:
* Informed consent will be obtained from the patient or the parents before any study related procedures.
* Patients of both genders older than 2 months
* The patient has a diagnosis of Fabry disease or a high-grade suspicion for Fabry disease
* High-grade suspicion present, if one or more inclusion criteria are valid:
* Positive family anamnesis for Fabry disease
* Pin and burning in the hands and feet
* Angiokeratomas
* Gastrointestinal problems
* Heart problems
* Kidney problems
EXCLUSION CRITERIA:
* No Informed consent from the patient or the parents before any study related procedures.
* Patients of both gender younger than 2 months
* No diagnosis of Fabry disease or no valid criteria for profound suspicion of Fabry disease